Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by Oak Ridge Investments LLC

Oak Ridge Investments LLC cut its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 6.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32,911 shares of the biotechnology company’s stock after selling 2,226 shares during the period. Oak Ridge Investments LLC’s holdings in Arrowhead Pharmaceuticals were worth $619,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the business. Nordea Investment Management AB raised its position in shares of Arrowhead Pharmaceuticals by 6.3% during the 4th quarter. Nordea Investment Management AB now owns 132,188 shares of the biotechnology company’s stock worth $2,463,000 after acquiring an additional 7,776 shares in the last quarter. Franklin Resources Inc. increased its stake in Arrowhead Pharmaceuticals by 9.4% in the third quarter. Franklin Resources Inc. now owns 19,251 shares of the biotechnology company’s stock valued at $373,000 after purchasing an additional 1,658 shares during the last quarter. World Investment Advisors LLC raised its holdings in Arrowhead Pharmaceuticals by 3.8% during the third quarter. World Investment Advisors LLC now owns 19,132 shares of the biotechnology company’s stock worth $371,000 after purchasing an additional 700 shares in the last quarter. Geode Capital Management LLC raised its holdings in Arrowhead Pharmaceuticals by 0.9% during the third quarter. Geode Capital Management LLC now owns 2,964,119 shares of the biotechnology company’s stock worth $57,426,000 after purchasing an additional 26,171 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new stake in shares of Arrowhead Pharmaceuticals during the 3rd quarter worth approximately $345,000. 62.61% of the stock is owned by hedge funds and other institutional investors.

Arrowhead Pharmaceuticals Trading Up 2.8 %

Shares of ARWR stock opened at $19.56 on Monday. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $17.05 and a twelve month high of $36.72. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 2.06. The business’s 50 day moving average is $20.81 and its two-hundred day moving average is $22.17. The company has a market capitalization of $2.43 billion, a P/E ratio of -3.90 and a beta of 0.97.

Wall Street Analyst Weigh In

Several brokerages recently commented on ARWR. Chardan Capital reiterated a “buy” rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Thursday, December 12th. Sanford C. Bernstein dropped their price objective on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating on the stock in a report on Friday, November 29th. Citigroup reduced their target price on Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Wednesday, November 27th. Piper Sandler dropped their price target on Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 27th. Finally, StockNews.com raised Arrowhead Pharmaceuticals to a “sell” rating in a research report on Friday, December 20th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $43.33.

Insider Activity at Arrowhead Pharmaceuticals

In related news, Director William D. Waddill sold 3,748 shares of the company’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $21.90, for a total transaction of $82,081.20. Following the transaction, the director now owns 44,125 shares of the company’s stock, valued at $966,337.50. This represents a 7.83 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider James C. Hamilton sold 32,729 shares of the firm’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $19.82, for a total value of $648,688.78. Following the completion of the sale, the insider now directly owns 272,122 shares of the company’s stock, valued at approximately $5,393,458.04. This trade represents a 10.74 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 146,473 shares of company stock worth $2,937,847 in the last three months. Insiders own 4.50% of the company’s stock.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.